Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients.
Joseph A MiccioWesley J TalcottVikram JairamHenry S ParkJames B YuMichael S LeapmanSkyler B JohnsonMartin T KingPaul L NguyenBenjamin H KannPublished in: Prostate cancer and prostatic diseases (2020)
Patients with low-risk prostate cancer selected for RP exhibited large OS differences despite similar PCSS compared to radiotherapy, suggesting OS differences are almost entirely driven by TSB. The quantities of these effects are important to consider when interpreting prostate cancer CER using national registries.